%PDF-1.3
%
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2017-01-31T19:48:35-08:00
2016-09-14T17:16:09+05:30
application/pdf
LRB-2016-0027-ver9-Nudelman_2P 124..126
uuid:62bfdc9f-19e6-4e19-92ab-eb9965f384d2
uuid:337a5296-2d45-48cd-9914-f8fcba155315
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F6 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(Most)-316.3(patients)-316.6(had)-309.7(avoided)-315.4(trauma)-315.5(to)-313.3(the)-315.6(arm,)-314.4(so)-313(only)-309.8(2.1%)]TJ
0 -1.1174 TD
[(had)-223.3(had)-223.3(an)-222.2(injection,)-223.5(only)-223.4(8.5%)-220.9(a)-221.1(blood)-224.5(draw,)-223(and)-223.3(no)-221.1(woman)]TJ
0 -1.1116 TD
[(who)-194.2(wore)-190.7(a)-186.6(compression)-193.9(garment)-189.9(while)-192.1(ying)-189.8(was)-189.5(allowed)-189.7(to)]TJ
T*
[(be)-285.6(included)-282.1(in)-278.8(the)-281.1(analysis.)]TJ
7.3823 0 0 6.5614 168.2078 696.6423 Tm
(1)Tj
9.843 0 0 9.843 69.7323 681.3352 Tm
[(The)-184.2(authors)-181.6(conclude)-185.2(that)-178.6(although)-183(their)-185.4(study)-178.2(suffers)-186.9(from)]TJ
-1.0137 -1.1174 TD
[(recall)-373.2(bias)-374.1(and)-367.3(short)-368.3(follow-up,)-371.5(they)-368.6(cannot)-371.9()50.8(afrmatively)]TJ
0 -1.1116 TD
[(state)-503.2(that)-501.2(risk-reduction)-501.7(practices)-504.2(have)-502.1(no)-497.5(effect)-499.7(on)-503.3(arm)]TJ
T*
[(swelling,)42.1()-277.5(but)-285.7(they)-282.2(hope)-282(to)-284.6(bring)-282.1(reasonable)-286.3(doubt)-282.1(to)-284.5()50.8(bur-)]TJ
0 -1.1174 TD
[(densome)-287.5(guidelines.)51.1()]TJ
1.0137 -1.1116 TD
[(The)-316.7(editorial)-318(reported)-316.5(a)-313.3(case)-313(where)-319.7(a)-313.3(violinist)-315.6(was)-316.2(coun-)]TJ
-1.0137 -1.1116 TD
[(seled)-301.5(to)-296.1(avoid)-300.5(compression)-303.4(with)-299.3(air)-298.3(ight)-293.6(and)-298.2(has)-303.8(remained)]TJ
0 -1.1174 TD
[(free)-311.9(from)-305.1(lymphedema.)-308.5(This)-305(was)-304.6(extrapolated)-312(to)-301.8(show)-304.6(how)]TJ
0 -1.1116 TD
[(burdensome)-285.1(risk-reduction)-288.6(behaviors)-282.9(are)-282.1(unnecessary.)]TJ
1.0137 -1.1116 TD
[(In)-186.5(the)-165.9(editorial,)-165.9()50.8(Time)-170.5(to)-163.6(Abandon)-171(Old)-165.6(Practices?)45.6()-162.3(the)-165.9(risk)]TJ
-1.0137 -1.1116 TD
[(of)-336.2(BRCL)-342.8(after)-336.2(sentin)-7.8(el)-337.6(node)-333.9(biopsy)-340.6(\(SNB\))-335.5(was)-339.2(reported)-339.5(at)]TJ
0 -1.1174 TD
[(5%,)-254.4(yet)-252.3(other)-248.7(data)-254.5(report)-255.5(that)-253.5(risk)-252(at)-251.2(25%)-252(when)-248.4(whole)-255.3(breast)]TJ
0 -1.1116 TD
[(radiation)-369.7(is)-370.8(included,)-366.2(as)-371.8(it)-365.3(radiates)-369.4(the)-367.5(level)-371(I/II)-367.3(nodes.)-367(As)]TJ
T*
[(noted)-312.1(in)-313.3(the)-309.9(editorial,)-315.7(with)-316.6(no)-307.5(standard)-316.3(diagnostic)-313(criterion,)]TJ
0 -1.1174 TD
[(incidence)-181.9(guidelines)-174.8(will)-178.5(varyconsiderably.)]TJ
7.3823 0 0 6.5614 239.1306 532.2329 Tm
(5)Tj
9.843 0 0 9.843 244.5165 527.8676 Tm
(Lymphedema)Tj
-18.7709 -1.1116 TD
[(is)-324.7(a)-324.8(clinical)-329.6(diagnosis,)-325.4(but)-326(as)-325.7()50.8(we)-322.1(are)-328.1(addicted)-329.3(to)-319.1(objecti-)]TJ
T*
[(cation)-256.9(and)-246.4(parameterization)-262.4(in)-250(medicine)-249.9(so)-249.7(it)-250.1(never)-255.5(seems)-250.6(to)]TJ
0 -1.1174 TD
[(stick.)46.4()]TJ
7.3823 0 0 6.5614 86.9669 499.4077 Tm
(10)Tj
9.843 0 0 9.843 69.7323 484.0439 Tm
[(The)-420.4(editorial)-421.7(described)-422.2(the)-419.3(article)-420.5(in)-417(question)-419(was)-419.8(as)-417.9(a)]TJ
-1.0137 -1.1116 TD
[()50.8(rigorous,)-427.9(prospective)-430.3(trial,)46.1()-421.5(rather)-429.5(than)-426.2(an)-423.8(observational)]TJ
0 -1.1174 TD
[(trial,)-333(with)-328.1(exclusion)-329.1(of)-324.7(women)-331.3(who)-326.7(wore)-328.9(compression)-332.2(gar-)]TJ
0 -1.1116 TD
[(ments)-347.7(during)-340.8(air)-344.4(travel,)-340.9(and)-344.3(a)-342.1(denition)-345.4(of)-342(arm)-339.7(volume)-343.2(in-)]TJ
T*
[(crease)-327.8(of)-324.7(10%)-321.1(as)-325.7(synonymous)-322.9(with)-328.1(BCRL.)-323.2(And)-326.7(although)-321.3(a)]TJ
T*
[(large)-405.3(number)-400.6(of)-405.3(women)-400.4(were)-405(followed,)-400.4(very)-403(few)-402.7(recalled)]TJ
0 -1.1174 TD
[(having)-284.4(experienced)-283()45(risky)50()-277.5(behavior)-281.9(in)-284.6(their)-283.4(arms.)]TJ
1.0137 -1.1116 TD
.013 Tc
[(Th)-5.4(e)-398.2(e)-6.5(dito)-5.4(ria)-6.5(l)-397.2(c)-6.5(oncl)-5.5(udes)-5.2(,)-399.4()46.5(on)-5.4(ly)-402.8(weig)-5.4(ht)-402.9(gai)-5.5(n)-397(a)-6.5(n).4(d)-402.8(i).3(nf)-5.3(ec-)]TJ
-1.0137 -1.1116 TD
.0128 Tc
[(t)-5.7(i).1(on)-5.6(s)-247.3(h)-5.6(ave)-254.4(b).2(ee)-6.7(n)-247.5(s)-5.4(how)-6.4(n)-247.5(t)-5.7(o)-253.2(b).2(e)-254.4(t).1(rue)-254.4(ri)-5.7(sk)-253.2(fa)-6.7(ctor)-5.5(s)-253(i).1(n)-253.2(d).2(eve)-6.7(l).1(op)-5.6(ing)]TJ
0 -1.1174 TD
.0142 Tc
[(lymphedem)-5.4(a).4(.)53.5()-286.4(T)-5.4(his)-292(i)1.5(s)-286.2(a)-287.6(vast)-286.5(over)-292.1(simplication,)-288.7(as)-292(radia-)]TJ
0 -1.1116 TD
.0124 Tc
[(t)-6.1(i)-.3(on)-6(,)-451.8(g)5.5(eneti)5.4(c)-450.6(pr)5.6(edi)5.4(s)0(p)5.5(o)-.2(si)5.4(ti)5.4(on,)-446(su)5.5(rgi)5.4(cal)-449.6(t)-.3(echn)5.5(iq)5.5(ue,)-446(a)-1.4(n)5.5(d)-449.5(bi)5.4(o-)]TJ
T*
.0114 Tc
[(markers)-191.1(hav)4.5(e)-198.2(all)-191.4(b)-1.2(een)-197(s)4.7(hown)-197(t)4.4(o)-197(b)]TJ
13.3568 0 TD
.0121 Tc
[(e)-197.5(r)-.5(i)5.1(s)-.3(k)-196.3(f)5.3(acto)5.2(rs)-196.2(i)5.1(n)-196.3(d)5.2(e)-1.7(velo)5.2(pi)5.1(ng)]TJ
-13.3568 -1.1174 TD
.0075 Tc
[(l)-5.2(y)-5.1(mp)-5.1(he)-6.3(de)-6.3(ma)-6.3(.)]TJ
1.0137 -1.1116 TD
0 Tc
[(The)-443.4(table)-440.1(included)-443.4(in)-440.1(the)-442.3(editorial)-438.9(reports)-446.5(that)-437.8(patients)]TJ
-1.0137 -1.1116 TD
[(should)-277.2(continue)-270.6(to)-273(get)-275.3(blood)-270.6(pressure)-275.6(measurements)-279.2(in)-273(their)]TJ
T*
[(at-risk)-440.8(arms,)-436.2(whereas)-438.1(the)-436.6(articles)-439.7(conclusion)-439.6(is)-434.1(only)-436.5(that)]TJ
0 -1.1174 TD
[(obtaining)-374.3(a)-376.6(blood)-374.3(pressure)-373.5(in)-376.7(the)-373.2(at-risk)-371.7(arm)-374.3(might)-375.6(not)-372.1(be)]TJ
0 -1.1116 TD
[(associated)-199.8(with)-189.8(increased)-193(arm)-190(swelling)-195.4(in)-186.6(the)-194.7(period)-192.2(that)-190.1(their)]TJ
T*
[(patients)-287.8(were)-284(measured.)]TJ
1.0137 -1.1174 TD
[(Clinicians)-400.6(reading)-390.3(this)-396.1(editorial)-398.6(can)-391.5(now)-395.8(place)-395(an)-395(auto-)]TJ
-1.0137 -1.1116 TD
[(mated)-308.7(cuff)-305(on)-307.5(a)-301.8(patient)-309.9(and)-304(state)-307.4(that)-305.3(the)-304.1(evidence)-307.3(supports)]TJ
T*
[(that)-270.8(it)-261.6(will)-270.6(never)-267(cause)-268(or)-267.1(trigger)-268.3(the)-263.8(onset)-271.6(of)-261.4(BCRL,)-271.3(yet)-263.8(the)]TJ
0 -1.1174 TD
[(evidence)-307.3(presented)-307.1(in)-301.8(the)-304.1(article)-305.3(does)-304.9(not)-302.9(support)-301.4(this)-304(prac-)]TJ
0 -1.1116 TD
[(tice)-404.4(alteration.)-410.1(The)-403.1(degree)-401.7(of)-405.3(medical)-404.4(invasiveness)-402.3(varies,)]TJ
T*
[(and)-309.7(the)-304.1(Ferguson)-303.3(article)-311.1(and)-304(accompanying)-313(editorial)-306.5(do)-301.7(not)]TJ
0 -1.1174 TD
[(differentiate)-238.3(a)-226.9(manual)-229.2(blood)-230.3(pressure)-229.6(reading)-229(from)-230.2(repetitive)]TJ
0 -1.1116 TD
[(automated)-285.6(readings.)]TJ
1.0137 -1.1116 TD
[(Us)20.2(e)-209.6(o)0(f)-203.8(c)15(om)19.6(p)16.2(r)0(e)19.7(s)0(s)21.2(i)16.1(on)-203.8(g)16.2(a)0(r)19.7(m)0(e)24.2(n)0(t)20.7(s)-208.3(wh)20(il)26.3(e)-215.4()0(y)21(i)16.1(ng)-203.8(e)15(x)0(c)19.7(l)0(u)26.5(d)0(e)19.7(d)-208.4(wo)20(m)15(e)0(n)]TJ
-1.0137 -1.1116 TD
[(fr)20.9(om)-228.1(th)20.7(e)-244.2(F)0(e)25.6(r)0(g)20.9(u)0(s)26.8(o)0(n)-232.6(t)0(r)20.7(i)16.1(al)-233.9(an)25.4(al)19.5(ys)21(i)16.1(s)0(.)-234.7(T)15(he)-233.7(to)26.5(pi)20.7(c)-244.2(i)0(s)-232.5(c)15(on)20.8(t)16.1(r)0(o)20.9(v)0(e)25.4(r)0(s)21.1(i)0(a)19.6(l)-237.4(fo)20.9(r)]TJ
0 -1.1174 TD
[(wo)20(m)15(e)0(n)-164.6(a)0(t)-164.8(r)0(i)20.7(s)0(k)26.8(.)-176.2(Un)20(fo)26.6(rt)20.7(un)26.6(at)19.5(e)15(l)0(y)-163.6(t)0(h)20.7(e)-175(da)19.7(t)16.1(a)-180.8(t)16.1(o)-179.6(c)15(o)0(n)20.8(c)15(lu)20.7(de)-164.6(th)26.5(at)-164.8(ai)19.6(r)-173.9()0(i)20.9(g)16.2(ht)]TJ
0 -1.1116 TD
[(pr)20.9(es)25.6(en)19.7(ts)-261.3(a)-278.7(r)16.2(is)20.9(k)-277.6(f)16.2(or)-267.1(t)16.1(h)0(e)-268.3(o)16.2(ns)21(et)-262.7(of)-261.4(BC)18.8(R)15.2(L)-278.8(do)-261.4(no)20.8(t)-271.9(h)0(a)25.4(v)0(e)-268.3(s)0(o)26.8(l)0(i)20.6(d)-271.8(cl)19.5(i)16.1(n)0(i)20.7(-)]TJ
T*
[(ca)18.5(l)-197.1(d)0(a)19.7(t)0(a)-187.8(t)0(o)-192.4(s)0(u)26.8(p)0(p)20.8(o)0(r)26.6(t)-202.8(th)20.7(e)-198.1(r)0(i)20.7(s)0(k)26.8(.)-205(T)15(h)0(e)-193.4(e)15(di)20.7(to)26.5(ri)20.7(al)-187.8(ci)19.5(t)16.1(e)0(d)-193.4(G)0(r)25.8(a)0(h)19.7(a)0(m)24.2(,)-199.3(a)-203.8(s)0(t)20.9(u)16.2(dy)]TJ
0 -1.1174 TD
[(wh)20(er)25.5(e)-393.9(a)-393.9(s)0(i)20.9(n)0(g)26.6(l)0(e)-383.6(s)0(u)21(r)0(g)26.6(e)0(o)19.7(n)-392.8(qu)26.6(er)19.7(ie)25.3(d)-392.8(h)0(i)20.7(s)-392.6(pa)25.4(ti)20.6(en)25.4(ts)20.9(,)-395.1(a)15(nd)-382.3(pe)19.7(r)16.2(f)0(o)20.9(r)0(m)25.4(e)0(d)]TJ
0 -1.1116 TD
[(tw)19.8(o-)26.6(po)20.8(in)26.5(t)-352.6(m)0(e)24.2(a)0(s)19.9(u)0(r)20.9(e)15(me)18.4(n)16.2(t)0(s)-342(a)0(n)25.4(d)-352.4(co)19.7(n)16.2(c)0(l)19.5(u)0(d)26.6(e)0(d)-343.2(t)0(h)26.5(a)0(t)-343.3()0(i)26.6(g)0(h)20.8(t)0(s)-336.2(o)0(f)-342(f)0(e)19.7(w)15.3(er)]TJ
T*
[(th)20.7(an)-176.2(4.)24.3(5)-191.2(h)0(o)20.8(u)16.2(rs)-180.5(m)15(i)0(g)20.7(h)0(t)-175.1(b)0(e)-181.9(s)0(a)25.6(f)0(e)19.7(.)-187.7(Th)25.4(is)-180.7(is)-174.9(po)20.8(or)-175(qu)20.8(al)25.3(it)20.6(y)-191.2(e)15(vi)20.7(de)25.4(nc)19.7(e)15(,)-193.5(a)15(n)0(d)]TJ
0 -1.1174 TD
[(sh)21(ou)26.6(ld)-261.5(n)16.2(o)0(t)-255.8(s)0(u)21(p)0(p)20.8(o)16.2(rt)-255.7(cl)19.5(in)26.5(ic)19.6(al)-256.9(pr)26.6(ac)18.5(ti)26.3(ce)18.5(.)]TJ
7.3823 0 0 6.5614 198.3684 104.8819 Tm
-.0162 Tc
(11)Tj
9.843 0 0 9.843 69.7323 89.5181 Tm
0 Tc
[(Lymphedema)-323.4(is)-324.7(not)-320.2(simply)-318.9(swelling,)-325.5(and)-315.5(Ferguson)-326.4(et)-320.3(al.)]TJ
-1.0137 -1.1116 TD
[(carefully)-474.4(omitted)-465.5(stating)-464.1(that)-466.6(risk-reducti)-9.9(on)-463(behaviors)-467.2(i)-18.5(n)-12.6(-)]TJ
0 -1.1174 TD
.0151 Tc
[(duc)-4.4(e)1.3(d)-187.6(l)2.4(ymphedema)-4.4(,)-184.2(b)-3.3(ut)-187.7(ra)-4.4(ther)-187.6(did)-187.6(n)2.5(ot)-182(a)-4.4(p)2.5(pear)-187.6(to)-187.6(cause)-188.7()48.6()2.5(a)-4.4(r)2.5(m)]TJ
0 -1.1116 TD
.0158 Tc
[(swe)-3.7(l)3.1(ling.)49.3()-417.2(T)2(he)-418.4(ac)-3.7(compa)-3.7(n)3.2(yi)]TJ
11.8823 0 TD
.013 Tc
[(ng)-425.8(ed)-5.4(it)-5.5(ori)-5.5(al)-426(dr)]TJ
6.2262 0 TD
.0141 Tc
[(ew)-419.8(a)-425.9(f)1.5(ar)-424.7(more)]TJ
7.4012 67.9184 TD
.0148 Tc
[(sw)-4.4(eeping)-435.5(a)-4.7(nd)-441.3(conc)-4.7(erning)-441.3(conclusion,)-437.9(a)1(nd)-441.3(re)-4.7(com)-4.8(mended)]TJ
0 -1.1174 TD
.0128 Tc
[(th)-5.6(at)-380.1(ro)-5.6(uti)-5.7(n).2(e)-381.1(b).2(l)-5.7(o).2(o)-5.6(d)-374.2(p)-5.6(r).2(e)-6.7(s).4(s)-5.4(u).2(r)-5.5(e)-375.4(m)-6.8(oni)-5.7(to)-5.6(ri)-5.7(ng)-380(in)-380(th)-5.6(e)-375.4(a)-6.7(t-)-5.5(ri)-5.7(sk)-380(ar)-5.5(m)]TJ
0 -1.1116 TD
.013 Tc
[(sh)-5.4(ou)-5.4(ld)-281.8(be)-283(s)-5.2(t).3(a)-6.5(n).4(d)-5.4(a)-.8(r)-5.3(d)-281.8(med)-5.4(ica)-6.5(l)-282(pr)-5.3(ac)-6.5(tic)-6.5(e.)]TJ
1.0137 -1.1116 TD
0 Tc
[(Lymphedema)-196.7(is)-192.2(an)-193.4(inammatory)-195.5(condition,)-193.5(a)-198.1(disruption)-195.5(of)]TJ
-1.0137 -1.1116 TD
[(the)-453.8(immune)-459.6(system,)-461.4(and)-459.5(the)-453.8(greatest)-461.6(risk)-459.3(for)-458.3(progressive)]TJ
0 -1.1174 TD
[(lymphedema)-218.7(is)-221(mild)-219(lymphedema.)-222.1(BCRL)-221.8(is)-221(under)-219.7(diagnosed)]TJ
0 -1.1116 TD
[(and)-269.4(under)-271.6(treated.)-274(It)-267.2(has)-275(profound)-267.9(impacts)-276.3(on)-267.1(the)-269.5(health)-274.1(and)]TJ
T*
[(quality)-256.9(of)-249.8(life)-259.2(of)-249.8(breast)-256.5(cancer)-258.9(survivors.)]TJ
7.3823 0 0 6.5614 471.4014 652.8187 Tm
(5)Tj
9.843 0 0 9.843 477.581 648.4534 Tm
[(Medical)-260(treatment)]TJ
-16.9393 -1.1174 TD
[(has)-332.6(moved)-336.2(toward)-337(reducing)-339.5(the)-332.9(risk)-338.4(by)-330.5(reducing)-339.5(the)-332.9(extent)]TJ
0 -1.1116 TD
[(of)-555.1(axillary)-552.9(clearance)-558.4(and)-557.4(actually)-554.1(proposing)-557(that)-553(lymph)]TJ
T*
[(node)-236(staging)-239.3(may)-236.1(be)-239.5(unnecessary)-241(in)-232.7(clinically)-245.5(node-negative)]TJ
0 -1.1174 TD
(patients.)Tj
7.3823 0 0 6.5614 344.0692 607.4644 Tm
(12,13)Tj
9.843 0 0 9.843 320.8251 593.6313 Tm
[(Is)-428.2(avoidance)-435.2(of)-428.4(medical)-433.2(trauma)-436.5(to)-428.5(an)-429.6(at-risk)-435.1(limb)-432.1(bur-)]TJ
-1.0137 -1.1116 TD
[(densome?)-364.7(Is)-364.8(an)-360.5(incurable)-365(condition)-362.8(worthy)-364.7(of)-359.3(minor)-363.9(alter-)]TJ
T*
[(ations)-220.9(in)-215.4(medical)-225.8(treatment?)-224.6(Should)-213.9(patient)-223.5(counseling)-220.8(avoid)]TJ
0 -1.1174 TD
[(over-simplication)-514.4(and)-505.6(explain)-511.4(the)-505.7(extent)-510.3(of)-509(our)-504.4(current)]TJ
0 -1.1116 TD
[(knowledge)-514.3(as)-510(well)-513.6(as)-515.8(our)-510.1(knowledge)-514.3(decits?)-519.1(Are)-512.2(risk-)]TJ
T*
[(reduction)-386.8(behaviors)-380.8(more)-386.9(burdensome)-383(for)-383.4(health)-383.6(care)-388(pro-)]TJ
0 -1.1174 TD
[(viders)-278.4(than)-282.2(patients?)]TJ
1.0137 -1.1116 TD
[(Education)-295.9(on)-295.9(risk)-298(reduction)-300.5(has)-298(been)-294.7(found)-299.2(to)-296.1(reduce)-298.1(the)]TJ
-1.0137 -1.1116 TD
[(incidence)-285.5(of)-278.6(lymphedema.)]TJ
1.0137 -1.1174 TD
[(The)-362.8(Ferguson)-360.9(article)-368.7(narrowly)-362.3(showed)-365.6(that)-362.9(self-reported)]TJ
-1.0137 -1.1116 TD
[(risk)-182.8(behaviors,)-182.6(which)-186.2(represented)-189.4(a)-180.8(small)-186.5(minority)-183.2(of)-180.7(women,)]TJ
T*
[(did)-256.9(not)-256.9(cause)-262.2(arm)-259.1(swelling)-264.5(in)-255.8(the)-258(period)-261.3(of)-261.4(their)-260.3(monitoring.)]TJ
0 -1.1174 TD
[(It)-278.8(concluded)-284.2(that)-282.3(further)-285.4(research)-283.9(was)-287.4(warranted.)-282.7(The)-282.1(edito-)]TJ
0 -1.1116 TD
[(rial)-328.3(concluded)-330.3(that)-328.4(only)-332.8(obesity)-325.7(and)-332.8(cellulitis)-330.7(cause)-331.3(BCRL,)]TJ
T*
[(and)-217.6(the)-217.7(current)-223.2(risk-reduction)-225.2(behaviors)-219.5(are)-224.5(never)-215.2(warranted.)]TJ
T*
[(The)-190(latter)-193.6(conclusion)-192(is)-192.2(neither)-188.8(supported)-195.3(by)-186.5(the)-194.7(literature)-193.5(nor)]TJ
0 -1.1174 TD
[(by)-278.7(the)-281.1(article)-282.3(that)-282.3(was)-281.6(reviewed.)]TJ
1.0137 -1.1116 TD
[(This)-385.7()50.8(debunking)50()-387(has)-384.4(the)-384.7(potential)-387.1(to)-388.2(harm,)-384.6(and)-384.6(is)-388(not)]TJ
-1.0137 -1.1116 TD
[(supported)-316.2(by)-313.2(the)-315.6(literature.)-317.9(Clinicians)-314.2(who)-315.2(quickly)-320.2(scanned)]TJ
0 -1.1174 TD
(their)Tj
/F7 1 Tf
2.35 0 TD
[(Journal)-509.9(Watch)]TJ
/F6 1 Tf
6.6928 0 TD
[(or)-509(read)-507.8(the)-511.4(editorial)-508.1(could)-507.9(possibly)]TJ
-9.0427 -1.1116 TD
[(counsel)-200(women)-198.8(that)-195.9(their)-197(requests)-200.9(to)-198.2(avoid)-196.9(iatrogenic)-199.2(harm)-202.6(to)]TJ
T*
[(their)-317.9(at-risk)-319.9(arms)-317.6(are)-316.6(unnecessary,)-319.3(and)-321.2(rather)-320(than)-316.7(allowing)]TJ
0 -1.1174 TD
[(women)-400.4(to)-394(make)-399.6(an)-395(informed)-402.9(decision)-397.1(and)-401.9(supporting)-396.9(that)]TJ
0 -1.1116 TD
[(decision,)-584.8(they)-581.7(wi)19.8(l)16.1(l)-571.4(tr)20.7(a)15(u)0(m)19.6(a)15(ti)20.6(ze)-557.5(th)20.7(ei)25.3(r)-571.3(a)0(t)19.5(-)0(r)26.7(i)0(s)20.9(k)-571.3(a)15(r)0(m)19.6(s)-571.1(i)16(n)-571.3(hi)20.7(g)16.2(h)]TJ
T*
[(pr)26.6(es)19.9(su)26.8(re)-291.3(a)15(u)0(t)20.7(o)0(m)25.4(a)0(t)19.5(e)15(d)-300.6(b)16.2(lo)20.7(od)-284.4(pr)20.9(e)15(s)0(s)21.2(u)0(r)26.6(e)-301.8(cu)25.4(ff)20.9(s)-294.6(a)0(n)19.7(d)-294.8(wi)19.8(t)16(h)-300.6(IM)-285.3(an)25.4(d)-300.6(I)16.2(V)]TJ
T*
[(in)26.5(je)19.6(c)15(t)0(i)20.6(o)0(n)26.6(s)0(,)-361.4(a)15(nd)-359.3(te)19.6(l)16.1(l)-369.9(wo)20(m)15(e)0(n)-360.5(t)0(h)26.5(a)0(t)-360.6(t)0(h)26.5(e)0(i)19.5(r)-369.7(c)15(o)0(n)20.8(c)0(e)24.3(r)0(n)20.9(s)-369.5(ar)25.5(e)-370.9(m)0(e)24.2(r)0(i)20.7(t)0(l)26.3(e)0(s)19.9(s)0(.)]TJ
0 -1.1174 TD
[(D)15.3(e)0(s)19.9(p)0(i)20.7(t)16.1(e)-497.6(t)0(r)20.7(e)0(m)24.2(e)0(n)19.7(d)16.2(ou)20.8(s)-496.2(c)0(l)19.5(i)16(ni)20.7(ca)24.3(l)-496.6(e)0(v)19.7(i)0(d)26.5(e)0(n)19.7(c)15(e)-497.6(t)0(h)20.7(a)0(t)-487.3(a)0(i)25.3(r)-496.4(i)20.9(gh)26.6(t)-502.3(m)15(ig)20.7(h)16.2(t)]TJ
0 -1.1116 TD
[(tr)26.5(ig)20.7(ge)25.4(r)-404.2(l)0(y)26.5(m)0(p)19.6(h)0(e)25.4(d)0(e)19.7(m)15(a,)-391.6(cl)19.6(i)16.1(n)0(i)20.7(c)0(i)25.3(a)0(n)19.7(s)-404.1(w)-13.5(i)-12.7(l)-12.7(l)-433.2(n)-12.6(o)-12.6(t)-427.4(a)-19.5(s)-12.4(s)-12.4(e)-19.5(s)-12.4(s)-427.1(a)-19.5(n)-12.6(d)-427.3(i)-12.7(n)-18.4(f)-12.6(o)-12.6(r)-18.3(m)]TJ
T*
.0139 Tc
[(wome)-5.6(n)-424.9(b)1.3(ased)-424.9(on)-424.9(their)-430.7(i)1.2(ndivid)]TJ
12.9593 0 TD
.013 Tc
[(ual)-426(r)-5.3(isk)-425.8(b)-5.4(ut)-426(co)-5.4(uns)-5.2(el)-426(the)-6.5(m)-.8(,)]TJ
-12.9593 -1.1174 TD
[(bas)-5.3(e)-.9(d)-374.1(o).3(n)-374.1(poor)-5.4(-qu)-5.5(alit)-5.6(y)-368.3(s)-5.3(tud)-5.5(i).2(es)-5.3(,)-370.7(t).2(ha)-6.6(t)-368.5(t)-5.6(her)-5.4(e)-369.5(is)-373.9(n)-5.5(o)-368.3(r)-5.4(i).2(sk.)-376.4(E)-.9(ven)]TJ
0 -1.1116 TD
.0132 Tc
[(Gra)-6.3(h).6(am,)-272.5(who)-270.1(s)-5(impl)-5.3(y)-264.4(q)-5.2(uer)-5.1(i).5(ed)-270.1(pa)-6.3(tien)-5.2(t).5(s)-269.9(a)-6.3(n)-10.9(d)-275.9(t)-5.3(o)-5.2(o)-10.9(k)-275.9(i)-5.3(n)-5.2(a)-12.1(d)-5.2(e)-6.3(q)-10.9(u)-5.2(a)-6.3(t)-11.1(e)]TJ
T*
.0187 Tc
[(mea)-6.6(s).5(ur)-5.4(emen)-5.4(ts)-5.2(,)-284.2(c)-6.6(onc)-6.6(lud)-5.4(e)-.8(d:)-293.6()52.2()-5.4(thi)-5.6(s)-287.5(is)-293.2(not)-293.6(to)-287.7(s)-5.2(a)-.8(y)-287.7(t)-5.6(hat)-287.8(t)-5.6(her)-5.4(e)-288.8(is)]TJ
0 -1.1174 TD
[(no)-379.8(ri)-5.6(sk,)-382.1(o).3(r)-379.8(n).3(o)-379.8(w)-.5(ome)-6.6(n)-374(a)-6.6(t)-374.2(r)-5.4(i).2(sk)-5.4(,)-376.4(o).3(r)-379.8(t).2(h)-5.4(a)-.8(t)-379.9(s).5(we)-6.6(lli)-5.6(ng)-379.8(nev)-5.4(e)-.8(r)-379.8(o).3(c-)]TJ
0 -1.1116 TD
.0203 Tc
[(curs.)48()]TJ
7.3823 0 0 6.5614 337.1526 236.3527 Tm
.0299 Tc
(11)Tj
9.843 0 0 9.843 320.8251 221.0456 Tm
0 Tc
[(Risk)-264.6(for)-273.9(lymphedema)-270.5(is)-272.8(multifactorial)-274.3(and)-269.4(women)-268(should)]TJ
-1.0137 -1.1174 TD
[(be)-337.4(given)-335.1(accurate)-343(counsel)-344(and)-332.8(supported)-345(in)-336.4(their)-335.2(decisions.)]TJ
0 -1.1116 TD
[(This)-195.6(need)-196.8(to)-198.2(debunk)-197.8(risk)-194.4(reduction)-196.8(does)-201.2(not)-193.5(relieve)-201.5(women)-198.8(of)]TJ
T*
[(burdensome)-480.9(guidelines,)-483.5(but)-475.7(over)-483.6(simplies,)-482.1(puts)-476.6(them)-485(in)]TJ
T*
[(harms)-279.4(way,)-285.2(and)-280.9(denies)-285.3(their)-283.4(reality)-286.9(of)-278.6(their)-283.4(risk)-280.8(of)-284.4(lymphe-)]TJ
0 -1.1174 TD
[(dema)-284.4(and)-280.9(prudent)-279.7(steps)-282.9(they)-282.2(can)-287.8(take)-283.3(to)-278.8(avoid)-283.3(this)-280.9(risk.)-284.2(De-)]TJ
0 -1.1116 TD
[(bunking)-197.9(prohibits)-200.1(truly)-201.6(informed)-201.3(decision)-201.3(making)-199.2(by)-203.8(patients)]TJ
T*
[(and)-280.9(providers.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 310.8472 114.6331 Tm
(References)Tj
/F6 1 Tf
9.2951 0 0 9.2951 315.496 98.589 Tm
[(1.)-500.4(Ferguson)-442.7(CM,)-437.5(Swaroop)-445.1(MN,)-440.3(Horick)-441.4(N,)-440.9(et)-443.1(al.)-443.1(Impact)-443.6(of)]TJ
1.2503 -1.1284 TD
[(ipsilateral)-555.6(blood)-549.1(draws,)-556.9(injections,)-549.6(blood)-555.2(pressure)-555.3(mea-)]TJ
0 -1.1223 TD
[(surements,)-442.4(and)-437.7(air)-439.4(travel)-437.4(on)-439.4(the)-437.1(risk)-440.6(of)-441.7(lymphedema)-439.6(for)]TJ
0 -1.1284 TD
[(patients)-397.3(treated)-393(for)-395.4(breast)-400.5(cancer.)-398.2(J)-395.7(Clin)-394.6(Oncol)-396.3(2016;)-390.5(34:)]TJ
0 -1.1223 TD
(691698.)Tj
/F9 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(LYMPHEDEMA)-337.8(RISK)-335.9(REDUCTION)-340.4(HAS)-332.3(NOT)-334(BEEN)-336.6(DEBUNKED)-22958.6(125)]TJ
ET
endstream
endobj
29 0 obj
<>stream
/GS1 gs
BT
/F6 1 Tf
9.2951 0 0 9.2951 66.6708 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(2.)-500.4(Ahn)-380.2(S,)-375.2(Port)-383.4(ER.)-379.1(Lymphedema)-381.1(precautions:)-380(time)-381.4(to)-377.9(aban-)]TJ
1.2503 -1.1223 TD
[(done)-334.1(old)-335.3(practices?)-339.9(J)-328.6(Clin)-339.7(Oncol)-335.3(2016;)-329.5(34:655658.)]TJ
-1.2503 -1.1284 TD
[(3.)-500.4(Beaulac)-345.3(SM,)-338(McNair)-341.2(LA,)-339.3(Scott)-336(TE,)-339.6(LaMorte)-341.7(WW,)-338.4(Kava-)]TJ
1.2503 -1.1223 TD
[(nah)-388.9(MT.)-391.9(Lymphedema)-393.3(and)-388.9(quality)-393.8(of)-386.9(life)-390.2(in)-390.1(survivors)-394(of)]TJ
0 -1.1283 TD
[(early-stage)-271.1(breast)-272.4(cancer.)-270.2(Arch)-264.8(Surg)-268.1(2002;)-268.5(137:12531257.)]TJ
-1.2503 -1.1223 TD
[(4.)-500.4(Paskett)-376.2(ED.)-369.8(Symptoms:)-373.4(lymphedema.)-372.6(Adv)-374.1(Exp)-374.4(Med)-369.8(Biol)]TJ
1.2503 -1.1284 TD
[(2015;)-335.6(862:101113.)]TJ
-1.2503 -1.1223 TD
[(5.)-500.4(Shaitelman)-283.2(SF,)-274.5(Cromwell)-286.9(KD,)-278(et)-278.4(al.)-278.5(Recent)-286.1(progress)-276.6(in)-280.3(the)]TJ
1.2503 -1.1284 TD
[(treatment)-495.9(and)-492.6(prevention)-499(of)-490.5(cancer-related)-500.8(lymphedema.)]TJ
0 -1.1223 TD
[(CA)-336(Cancer)-337.8(J)-328.6(Clin)-339.7(2015;)-329.5(65:5581.)]TJ
-1.2503 -1.1284 TD
[(6.)-500.4(Cheville)-378.6(A.)-379.9(www.breastcancer.org/treatment/lymphedema/)]TJ
1.2503 -1.1223 TD
[(evaluation/diagnosis.)-337.9(Accessed)-341.1(September)-335.3(7,)-335.7(2016.)]TJ
-1.2503 -1.1284 TD
[(7.)-500.4(Jeffs)-367.7(E,)-362(Purushotham)-362.9(A.)-361.6(The)-366.4(prevelance)-365.8(of)-362.5(lymphoedema)]TJ
1.2503 -1.1284 TD
[(in)-341.3(women)-347.6(who)-343.6(attended)-348.1(an)-339.9(information)-349.8(and)-340.1(exercise)-348.2(class)]TJ
0 -1.1223 TD
[(to)-591.3(reduce)-595.2(the)-595.7(risk)-593.1(of)-588.1(breast)-595.7(cancer-related)-598.4(upper)-592.8(limb)]TJ
0 -1.1284 TD
[(lymphoedema.)-336.1(Springerplus)-334.7(2016;)-335.6(5:21.)]TJ
-1.2503 -1.1223 TD
[(8.)-500.4(Stout)-417.2(NL,)-418.6(Pfalzer)-423.1(LA,)-418.6(et)-418.7(al.)-418.7(Preoperative)-421.4(assessment)-424.3(en-)]TJ
1.2503 -1.1284 TD
[(ables)-349.2(the)-351.7(early)-352.4(diagnosis)-356.4(and)-346.2(successful)-354.7(treatment)-355.6(of)-350.3(lym-)]TJ
0 -1.1223 TD
[(phedema.)-336.5(Cancer)-337.8(2008;)-329.5(112:28092819.)]TJ
-1.2503 -1.1284 TD
.0137 Tc
[(9)13.7(.)-486.7(www.lnni.org/publ)]TJ
9.1001 0 TD
[(ications/crestgu)-4.7(idel)]TJ
8.0815 0 TD
.0139 Tc
[(inesforth)-4.5(e)3.5(diagnosis)]TJ
-15.9312 -1.1223 TD
.0134 Tc
[(ass)-4.1(e)3(s)-4.1(s)1.9(ment)-4.5(an)-5(dmanagementoym)-4.6(phoedema.)]TJ
25.2569 22.5062 TD
0 Tc
[(10.)-500.5(Cheville)-335.9(A.)-337.2(Personal)-336.6(correspondence.)]TJ
0 -1.1223 TD
[(11.)-500.5(Graham)-500.7(PH.)-492.8(Compression)-498.1(prophylaxis)-494(may)-498.2(increase)-494.6(the)]TJ
1.7505 -1.1284 TD
[(potential)-562.5(for)-560.1(ight-associated)-563.1(lymphoedema)-561.7(after)-556(breast)]TJ
0 -1.1223 TD
[(cancer)-337.2(treatment.)-337.4(Breast)-338.2(2002;)-335.6(11:6671.)]TJ
-1.7505 -1.1283 TD
[(12.)-500.5(Lucci)-406.9(A,)-404.3(McCall)-402.5(LM,)-404.1(et)-400.4(al.)-406.5(Surgical)-404(complications)-407.4(asso-)]TJ
1.7505 -1.1223 TD
[(ciated)-463.7(with)-458.4(sentinel)-458.3(lymph)-463.3(node)-456.1(dissection)-457.7(\(SLND\))-464.8(plus)]TJ
0 -1.1284 TD
[(axillary)-272.4(lymph)-262(node)-267.1(dissection)-268.6(compared)-271.8(with)-269.4(SLND)-264.7(alone)]TJ
0 -1.1223 TD
[(in)-237.6(the)-235.8(American)-236.2(College)-238.7(of)-234.4(Surgeons)-235.4(Oncology)-232.1(Group)-236.4(Trial)]TJ
0 -1.1284 TD
[(Z0011.)-338.2(J)-334.7(Clin)-333.6(Oncol)-335.3(2007;)-329.5(25:36573663.)]TJ
-1.7505 -1.1223 TD
[(13.)-500.5(Del)-463.1(Reigo)-466.6(J,)-462.9(Diaz-Ruiz)-466.7(MJ.)-462.3(The)-464(impact)-459.1(of)-466.1(preoperative)]TJ
1.7505 -1.1284 TD
[(axillary)-351.7(ultrasonography)-354.8(in)-347.4(T1)-349.8(breast)-351.7(tumours.)-349.2(Eur)-352.3(Radiol)]TJ
0 -1.1223 TD
[(2016;)-335.6(26:10731081.)]TJ
9.843 0 0 9.843 441.014 580.7054 Tm
[(Address)-337.6(correspondence)-337.8(to:)]TJ
/F7 1 Tf
2.2002 -1.1116 TD
[(Judith)-336.3(Nudelman,)-332.2(MD)]TJ
-6.9404 -1.1116 TD
[(Providence)-339.3(Community)-336.7(Health)-337.2(Centers)]TJ
6.7446 -1.1174 TD
[(530)-331.6(North)-334.8(Main)-333.9(Street)]TJ
.3513 -1.1116 TD
[(Providence,)-337(RI)-337.4(02904)]TJ
-6.4278 -2.1253 TD
(E-mail:)Tj
/F6 1 Tf
3.3982 0 TD
(judith_nudelman@brown.edu)Tj
/F9 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(126)Tj
48.9583 0 TD
(NUDELMAN)Tj
ET
endstream
endobj
32 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
34 0 obj
<>stream
8;Z\7!>:#-%-.@0m!!X9FJ,uIPleSBghq0_+c0m5aFcQF2.F)LcMric<#t;U1BJ^c
4noA[m3CA>9`'i[@pb?iMB?rVpI0I5*r0$_4eL1mqpU7:Ia_`3O/r!P?li'9D7,b'
Ki0'I[l??r@6-)V6m^guOl
W[ed4O1Ae$<2=AO=MdBWooo%/OYB_]A6+IcO4Hr
endstream
endobj
21 0 obj
<>stream
8;Z]"6'fD2$q#CA$i2ojC7E_=A.q&;cDt#`!ocir5g4\b:lhPM='=GX33Uha\pS's
iU&pl+Vf5/ro.Lk/6bZN1*,8=TZ1\UhKe:m=4n^/QOUB^CI>Dsl
.1g22D,^"-i4:WrE3NO*ibbrd%=;(7?MA.$a1@QQc"PA`jd1Z>$1h^$4qU6n)4(k%
g`@t0I_^Bs6+'s(Rm"W>.pNFik#$3YQaT&SUkc[,_B"6HgF7B]@"&j*+7WJ'Qua$s
bDq#7h&%)9dt3'nSpbt#+.KdiK5;#H_\IZDq7Sc=>0*Ad>-)We;'e@"V3Q>U>4hMX
O*NA5o
endstream
endobj
30 0 obj
<>stream
8;Z\u9+HV/$q#CA$g'Jp"<*ZI:8$'8/GqC3,rg)CR>DMZ)n]usZBm&pB(rOrJV@+L
W2WG;ILb6KO:c*1?&jq3EKf6@&g`4FI.Y53d7:d'p\!A[k`iRmFVZjG
>,6H#8*&TB`gJ).cZ$GCp&!k&1W`_k5/8t,bJ<)/UJ_ET7t(u_H20Z"?,U6Zh1r0O
fBOmI9s!5B`a(qbZRphA63n`f&4-XG`$.AI!37uZ4o~>
endstream
endobj
38 0 obj
<>
endobj
39 0 obj
<>stream
HtUɎ8WH
bFŹ;2H̡-3&В92(ӞI`bW>~Nr}(Dx!4Z~y+[8m,Nj*Y;,
}a/8NJ)5{m~hCd(285w*nrÞ}j5ܰw}c={ێVovnNvq>07Rb%Z?oxGW}LU-T=V4/T+k#)|zޖ+-caSWP[/J^IY=)91ʄhU'DaKBgM
Yyd#SXe"vq8'°i<ŵaЅ< OǮm6ˉ₽Α$sd!Kz^a7Q4"#kxj(ZUDBAW5jvUJ(֎by61D5K6cگq$m)=RBo #SNo
2v2S?"`gNݖl
2*M8M4zCKa1gCP*ÞXe3 azDTG@Mjg& v
#)]9
aJ 1ƃC9&Z4\@tIzPafQ6-jOC7i)H_@FKh߱/<-7$kG-Hu.ѨV;ŶDb'Eʚ0D1HkaɳvtsHgWo_/iYCk[WYj!`6TIBy琬1}[Af]*/K%Do#6pKHs?t0^FM;a~}%#}/]_vޝk)SZnwQ:-
ϥu}]DEi0vs7
ʰI"(/`P!
;Jjzwo*hD-)(4jdNCSN0䓸\;m)*-QWOCI՝ˉO~l챰XhSݱnſ S.S
endstream
endobj
40 0 obj
<>stream
HlVM6#ՉK(dKvreY}H=?wO q&9A|<<@K6=YV?\X&[3&ix9ݦ63Imq1&'-^&ע|ֻ79ʑ&Mal`Kؕ#pd3vm>B&Nbmx_,13NTB=o4ṣ/9~N ORBmGvi
zgyVP 1!÷BB|i-d9mڀmI[pHpo9l\ޒiL8Bj!Y)$.a9LV*
+in3r8Gʧ
$أZzsٕ>Ph}
9:vjbo^!h}4;1f
hg`$Uĥp5ZP_!Ḛ[6+͇17-G伢_SY.7P'䘛e<Zʊ4JqϚ UdE(n̜h[.#C7@tkC$籁a1,pPjҚK@"#Sn _dFY0Q
JvF^ sEA!xEдz=;Oյ
d pĩcaG;At Mj&%N2NwxJ$)C7EPbH>@Kp,MFG@<+dJe99z%uG9Nz\xʺMGQEː[SHg^{R"1i0ʂcP@qҰ*CfaK41j ȑGb
[ +лȁpVP^Y-y!2-pф9RDȘd+A`=aE7DD>TZ+\g~A|k2~ګcd< h"R
endstream
endobj
41 0 obj
<>stream
HtUn6+fS@.2mi,Rtʌprw?=$3I$FCP~Sle^l+7e&oUm˶bQ!ʦV.$a[wjvyN"V%rZMlKZ5